Bayer Sues Teva, Aurobindo to Block Kerendia Kidney-Drug Copies

Copies of Bayer AG’s Kerendia proposed by Teva Pharmaceutical Industries Ltd. and Aurobindo Pharma Ltd. infringe a patent for the chronic-kidney-disease drug that doesn’t expire for nearly a decade, Bayer alleged in separate federal lawsuits.

Aurobindo and Teva’s generic 10- and 20-milligram tablets of finerenone, Kerendia’s active ingredient, infringe US Patent No. RE49,826, according to Bayer’s complaints filed Thursday in the US District Court for the District of Delaware.

• Kerendia is used to reduce kidney- and heart-failure risks in adults with diabetes-related chronic kidney disease and heart-failure patients with preserved ejection fraction—meaning their hearts pump normally but don’t ...